secwatch / observer
8-K filed April 2, 2026, 7:59 PM ET ticker CAI CIK 0002019410
debt confidence high sentiment neutral materiality 0.50

Caris Life Sciences enters $400M term loan and $300M delayed draw facility with Blue Owl and Blackstone

Caris Life Sciences, Inc.

item 1.01item 1.02item 2.03

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0002019410-26-000019
form_type
8-K
ticker
CAI
cik
0002019410
company_name
Caris Life Sciences, Inc.
filed_at
2026-04-02T23:59:59+00:00
discovered_at
2026-05-14T18:02:33.389002+00:00
generated_at
2026-05-15T07:53:27.175975+00:00
sec_items
["1.01", "1.02", "2.03"]
event_type
debt
sentiment
neutral
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0002019410-26-000019
json_url
https://secwatch.observer/filing/0002019410-26-000019.json
markdown_url
https://secwatch.observer/filing/0002019410-26-000019.md
text_url
https://secwatch.observer/filing/0002019410-26-000019.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/0002019410-26-000019-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

3f4acc9b8602a48859e8ac04773926e22112e7e7

Caris Life Sciences, Inc. incurred credit facility of $400,000,000 initial term loan, up to $300,000,000 delayed draw facility, and up to $500,000,000 uncommitted incremental with Blue Owl Capital and Blackstone at Term SOFR Rate or Base Rate plus 5.00% or 4.00%, respectively maturing Initial Term Facility matures in April 2031; Delayed Draw Facility available through August 2027.

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

SEC 8-K Item 2.03/2.04 confidence 0.95 SEC evidence

966236c1aafd829ee691b98169036019c38ff122

Caris Life Sciences, Inc. entered into New Credit Agreement with Blue Owl Capital and Blackstone valued at Senior secured credit facilities: $400M initial term loan, $300M delayed draw, $500M incremental fac (effective 2026-04-01).

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

b6e34681e3b08597ea60b0af74694e236d6571a8

Caris Life Sciences, Inc. terminated Previous Credit Agreement with Wilmington Trust, National Association valued at Repaid all outstanding indebtedness and terminated guarantees, liens, and security interests under t (effective 2026-04-01).

On the Closing Date, the Company used proceeds under the Initial Term Facility to repay all outstanding indebtedness under that certain credit agreement, dated as of January 18, 2023, by and among the Company, certain of the Company’s subsidiaries, the lenders from time to time party thereto and Wilmington Trust, National Association, as administrative agent, as amended (the “ Previous Credit Agreement ”). The Company terminated all guarantees, liens and other security interests granted under and terminated the Previous Credit Agreement.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

TCPC

BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities

BlackRock TCP Capital Corp. June 1, 2026, 4:50 PM ET debt Items 1.01, 1.02, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 1.02, 2.03 same event type: debt similar materiality

This filing

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

Comparable filing

Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the " Closing Date "), BlackRock TCP Capital Corp. (the " Company "), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the " CLO Transaction "). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C

Filing page SEC filing

VIASP

Via Renewables enters $300M senior secured revolving credit facility, replaces prior agreement

Via Renewables, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 1.02, 2.03, 3.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 1.02, 2.03 same event type: debt similar materiality

This filing

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

Comparable filing

In connection with entering into the Credit Agreement, the Company entered into an amended and restated subordinated promissory note (Note No. 9) (the “Subordinated Debt Facility”) with Spark HoldCo and Retailco, LLC (“Retailco”). The Subordinated Debt Facility allows the Company to draw advances in increments of no less than $1.0 million per advance up to $25.0 million through November 6, 2029.

Filing page SEC filing

EHC

Encompass Health issues $500M 5.875% notes due 2034; to redeem $400M of 4.500% notes due 2028

Encompass Health Corp June 1, 2026, 4:26 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03 same event type: debt similar materiality

This filing

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

Comparable filing

On May 29, 2026, Encompass Health Corporation (the “Company”) completed the issuance and sale of $500 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the “Notes”), along with the related guarantees of the Notes by certain of the Company’s subsidiaries (the “Guarantees”), in a private offering.

Filing page SEC filing

PGIM

PGIM Private Credit Fund enters $100M credit facility with $500M accordion option

PGIM Private Credit Fund May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03 same event type: debt similar materiality

This filing

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

Comparable filing

Repo Rate Average; and for Australian‐dollar advances, Bank Bill Swap Rate), in each case subject to a 0.25% floor. The initial facility amount of the Credit Facility is $100 million, with an accordion feature that permits increases, with the consent of the facility agent and the lenders, up to an aggregate commitment of $500 million. The Credit Facility has

Filing page SEC filing

LYV

Live Nation VenueCo closes €610M secured notes issuance backed by 4 venues

Live Nation Entertainment, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03 same event type: debt similar materiality

This filing

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

Comparable filing

On May 8, 2026, Live Nation VenueCo, LLC (“VenueCo”), a bankruptcy-remote, special purpose vehicle owned by certain bankruptcy-remote, special purpose entities (the “Participants”), which are indirect subsidiaries of Live Nation Entertainment, Inc. (the “Company”), closed its previously announced issuance of €610 million aggregate principal amount of fixed rate senior secured notes (the “Notes”).

Filing page SEC filing

HNOI

HNO International issues $67,500 convertible note and warrant to Monroe Street Capital

HNO International, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03 same event type: debt similar materiality

This filing

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

Comparable filing

On May 5, 2026, HNO International, Inc. (the "Company") entered into a Securities Purchase Agreement (the "MSC Purchase Agreement") with Monroe Street Capital Partners, LP, a Delaware limited partnership (the "MSC Buyer"), pursuant to which the Company issued to the MSC Buyer a Convertible Promissory Note in the principal amount of $67,500

Filing page SEC filing

JERSEY CENTRAL POWER & LIGHT CO

JCP&L issues $350M of 4.600% Senior Notes due 2030 for refinancing and capex

JERSEY CENTRAL POWER & LIGHT CO May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03 same event type: debt similar materiality

This filing

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

Comparable filing

On May 6, 2026 (the “Closing Date”), Jersey Central Power & Light Company (the “Company”) completed its offering of $350,000,000 aggregate principal amount of its 4.600% Senior Notes due 2030 (the “Notes”)

Filing page SEC filing

BKNG

Booking Holdings issues $750M of 5.375% Senior Notes due 2036

Booking Holdings Inc. May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 8.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03 same event type: debt similar materiality

This filing

On April 1, 2026 (the “ Closing Date ”), Caris Life Sciences, Inc., a Texas corporation (the “ Company ”) entered into a Financing Agreement, dated as of the Closing Date (the “ New Credit Agreement ”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders. The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “ Initial Term Facility ”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“ Delayed Draw Facility ”), and (c) an uncommitted incremental facility in an aggregate principal amou

Comparable filing

in connection with the sale of $750,000,000 aggregate principal amount of the Company’s 5.375% Senior Notes due 2036

Filing page SEC filing

Source: SEC EDGAR
accession 0002019410-26-000019
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.